Pinnacle Research Institute — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$91,476	16
2022	Research	$726,508	97
2021	Research	$1,185,511	23
2020	Research	$223,947	9
2019	Research	$158,074	6

Breakdown

Who paid Research payments · program years 2019–2023

Regeneron Pharmaceuticals, Inc. $1,378,811 112 payments
Novartis Pharmaceuticals Corporation $748,571 11 payments
Allergan Inc. $181,071 9 payments
Apellis Pharmaceuticals, Inc. $71,063 17 payments
Roche TCRC, Inc. $6,000 2 payments

Studies the money was for Research payments · program years 2019–2023

A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $1,374,061 111 payments
A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $222,190 2 payments
Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $181,071 9 payments
A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $160,632 3 payments
A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $128,891 1 payment
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab VS. Aflibercept in Patients With Visual Impairment Due to Diabetic MacUlar Edema (Kingfisher) $113,311 2 payments
A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $80,774 1 payment
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration $38,507 5 payments
A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced Chronic Pain (Cicp) Following Photorefractive Keratectomy (PRK) Or Laser-Assisted in Situ Keratomileusis (Lasik) Surgeries $25,203 1 payment
A 56-Week Phase Iiib/Iv, Open-Label, One-Arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 MG in A Treat-To-Control Regimen With Maximum Treatment Intervals Up to 20 Weeks for the Treatment of Patients With Neovascular Age-Related Ma $17,569 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.